StockData
enGene Therapeutics Inc. logo

enGene Therapeutics Inc. (ENGN) bonds

ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 8, 2026Score 3/30
$1.72−0.17 (-8.99%)

Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%

Debt

Borrowings on the balance sheet, Jul 31, 2026

Total debt
$25.16M
Long-term debt
Net debt
-$15.87M
After $41.03M of cash
Implied interest rate
15.84%
FY2025 interest ÷ average debt
Interest coverage
-41.1×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Notes and loans outstanding

As tagged in enGene Therapeutics's 10-Q for the period ended Jul 31, 2026

IssueMaturesCarrying value
2026 Term LoanJan 1, 2030$27.73M
2021 Loan and Security Agreement–$24.57M
Term Loan–$27.73M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

See a number that looks wrong?